Affordable Access

Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema.

Authors
  • Helm, F
  • Helm, T N
Type
Published Article
Journal
Cutis
Publication Date
Mar 01, 1987
Volume
39
Issue
3
Pages
219–223
Identifiers
PMID: 3470169
Source
Medline
License
Unknown

Abstract

We report the case of a patient with scleromyxedema with abnormal monoclonal gamma globulin of the kappa type who was treated with melphalan (Alkeran), an alkylating agent. After nine and one-half years of therapy, the patient showed myelomonocytic leukemia. The risk of secondary malignancies must be considered when weighting the benefits and risks of melphalan treatment.

Report this publication

Statistics

Seen <100 times